Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Elize PietersenKim AndersonHelen CoxKeertan DhedaAihua BianBryan E ShepherdTimothy R SterlingRobin M WarrenYuri F van der HeijdenPublished in: PloS one (2023)
We found that incomplete treatment for second-line injectables and PAS during hospitalization was higher than for other anti-TB drugs. To maximize treatment success, interventions to improve person-centered care and mitigate adverse events may be necessary in cases when PAS or amikacin (2020 WHO recommended Group C drugs) are needed.